Some books move forward. Others circle. "Paradiso 17" by Hannah Lillith Assadi and "Python's Kiss" by Louise Erdrich belong ...

PycoClaw is a MicroPython-based platform for running AI agents on ESP32 and other microcontrollers that brings OpenClaw ...

JetBrains, the company behind the popular PyCharm IDE, offers a free introductory Python course. This is a pretty neat option if you like learning by doing, especially within a professional coding ...

The Contagious Interview campaign weaponizes job recruitment to target developers. Threat actors pose as recruiters from crypto and AI companies and deliver backdoors such as OtterCookie and ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. If you are wondering whether Recursion Pharmaceuticals is ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

So, you’re looking to get better at coding with Python, and maybe you’ve heard about LeetCode. It’s a pretty popular place to practice coding problems, especially if you’re aiming for tech jobs.

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...